Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F24%3A00013683" target="_blank" >RIV/00023736:_____/24:00013683 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/24:00138533 RIV/61989592:15110/24:73626322 RIV/65269705:_____/24:00081054 RIV/00098892:_____/24:10158754
Result on the web
<a href="https://doi" target="_blank" >https://doi</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2023.284678" target="_blank" >10.3324/haematol.2023.284678</a>

Result language
angličtina
Original language name
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Original language description
The optimal treatment strategies for hematological malignancy patients with COVID19 are still unclear with respect to the selection and timing of anti-viral as well as anti-inflammatory therapies. Our study demonstrates that dexamethasone treatment for SARS-CoV-2 infection is related to increased mortality in hematological malignancy patients, even during the omicron wave with most patients being fully vaccinated. Data included were exported from the EPICOVIDEHA registry.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)